Biosimilars in Oncology – Sandoz and Amgen are Main Players in the Development of Biosimilars in Oncology
DUBLIN, Jan. 22, 2024 /PRNewswire/ — The “Thematic Intelligence – Biosimilars in oncology” report has been added to ResearchAndMarkets.com’s offering. The report provides an insight into the percentage of cancer patients treated with biosimilars, the price of these ag
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grand Canyon Education, Inc. – LOPE
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Grand Canyon Education, Inc. (“GCE” or the “Company”) (NASDAQ: LOPE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (NASDAQ: MIST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of B. Riley Financial – RILY
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of B. Riley Financial (“B. Riley” or the “Company”) (NASDAQ: RILY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7
Vistex Mourns the Passing of Vistex Founder, CEO and Chief Architect Sanjay Shah
HOFFMAN ESTATES, Ill., Jan. 22, 2024 /PRNewswire/ — Vistex announced today the unexpected passing of Vistex Founder, CEO and Chief Architect Sanjay Shah. Sanjay Shah and Raju Datla, President of Vistex, were seriously injured in a tragic accident that occurred at a company event on January 18,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. – IOVA
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Endeavour Mining plc – EDVMF
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Endeavour Mining plc (“Endeavour” or the “Company”) (OTC: EDVMF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, e
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Algoma Steel Group Inc. – ASTL
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Algoma Steel Group Inc. (“Algoma” or the “Company”) (NASDAQ: ASTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. – NEO
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. – GRFS
NEW YORK, Jan. 22, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. (“Grifols” or the “Company”) (NASDAQ: GRFS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
